ASBP
Aspire Biopharma Holdings, Inc.
Biotechnology
Market Cap$7M
5Y Perf.-98.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ASBP vs YCBD
Revenue, margins, valuation, and 5-year total return — side by side.
YCBD
cbdMD, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$8M
5Y Perf.-81.9%
ASBP vs YCBD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ASBP | YCBD |
|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
| Market Cap | $7M | $8M |
| Revenue (TTM) | $2K | $19M |
| Net Income (TTM) | $-32M | $-328M |
| Gross Margin | 45.5% | 59.8% |
| Operating Margin | -10314.4% | -5.7% |
| Total Debt | $1M | $778M |
| Cash & Equiv. | $4K | $2M |
ASBP vs YCBD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ASBP
YCBD
| Stock | Jan 25 | May 26 | Return |
|---|---|---|---|
| Aspire Biopharma Ho… (ASBP) | 100 | 1.2 | -98.8% |
| cbdMD, Inc. (YCBD) | 100 | 18.1 | -81.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ASBP vs YCBD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: YCBD leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Aspire Biopharma Holdings, Inc. is the stronger pick specifically for operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
ASBP
Aspire Biopharma Holdings, Inc.
The Long-Run Compounder
ASBP is the clearest fit if your priority is long-term compounding.
- -98.7% 10Y total return vs YCBD's -100.0%
- -13.2% ROA vs YCBD's -27.8%
Best for: long-term compounding
YCBD
cbdMD, Inc.
The Income Pick
YCBD carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 0.66
- Rev growth -1.5%, EPS growth 39.1%, 3Y rev CAGR -18.5%
- Lower volatility, beta 0.66, current ratio 2.05x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | YCBD | -1.5% revenue growth vs ASBP's -13.7% |
| Quality / Margins | YCBD | -6.5% margin vs ASBP's -16K% |
| Stability / Safety | YCBD | Beta 0.66 vs ASBP's 1.74 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | YCBD | -8.8% vs ASBP's -52.6% |
| Efficiency (ROA) | ASBP | -13.2% ROA vs YCBD's -27.8% |
ASBP vs YCBD — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLYCBDLAGGINGASBP
ASBPAspire Biopharma Hold…
1leads
YCBDcbdMD, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs ASBPMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
YCBD4/4
Valuation MetricsMultiples, price ratios, and targets
YCBD1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ASBP3/4
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
YCBD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
YCBD leads this category, winning 4 of 4 comparable metrics.
Income & Cash Flow (Last 12 Months)
YCBD is the larger business by revenue, generating $19M annually — 9669.9x ASBP's $1,941. YCBD is the more profitable business, keeping -6.5% of every revenue dollar as net income compared to ASBP's -16352.0%.
| Metric | ASBPAspire Biopharma … | YCBDcbdMD, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $1,941 | $19M |
| EBITDAEarnings before interest/tax | -$28M | -$286M |
| Net IncomeAfter-tax profit | -$32M | -$328M |
| Free Cash FlowCash after capex | -$4M | -$853M |
| Gross MarginGross profit ÷ Revenue | +45.5% | +59.8% |
| Operating MarginEBIT ÷ Revenue | -10314.4% | -5.7% |
| Net MarginNet income ÷ Revenue | -16352.0% | -6.5% |
| FCF MarginFCF ÷ Revenue | -1811.5% | -16.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +980.1% |
| EPS Growth (YoY)Latest quarter vs prior year | — | +83.6% |
YCBD leads this category, winning 4 of 4 comparable metrics.
Valuation Metrics
YCBD leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ASBPAspire Biopharma … | YCBDcbdMD, Inc. |
|---|---|---|
| Market CapShares × price | $7M | $8M |
| Enterprise ValueMkt cap + debt − cash | $9M | $784M |
| Trailing P/EPrice ÷ TTM EPS | -0.60x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 0.44x |
| Price / BookPrice ÷ Book value/share | — | 0.46x |
| Price / FCFMarket cap ÷ FCF | — | — |
YCBD leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
ASBP leads this category, winning 3 of 4 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), YCBD scores 5/9 vs ASBP's 2/9, reflecting solid financial health.
| Metric | ASBPAspire Biopharma … | YCBDcbdMD, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | — | -3.6% |
| ROA (TTM)Return on assets | -13.2% | -27.8% |
| ROICReturn on invested capital | — | -0.4% |
| ROCEReturn on capital employed | — | -47.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 |
| Debt / EquityFinancial leverage | — | 107.70x |
| Net DebtTotal debt minus cash | $1M | $776M |
| Cash & Equiv.Liquid assets | $3,633 | $2M |
| Total DebtShort + long-term debt | $1M | $778M |
| Interest CoverageEBIT ÷ Interest expense | -9.19x | — |
ASBP leads this category, winning 3 of 4 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — ASBP and YCBD each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ASBP five years ago would be worth $135 today (with dividends reinvested), compared to $6 for YCBD. Over the past 12 months, YCBD leads with a -8.8% total return vs ASBP's -52.6%. The 3-year compound annual growth rate (CAGR) favors YCBD at -63.0% vs ASBP's -76.2% — a key indicator of consistent wealth creation.
| Metric | ASBPAspire Biopharma … | YCBDcbdMD, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +13.1% | -28.4% |
| 1-Year ReturnPast 12 months | -52.6% | -8.8% |
| 3-Year ReturnCumulative with dividends | -98.7% | -94.9% |
| 5-Year ReturnCumulative with dividends | -98.7% | -99.9% |
| 10-Year ReturnCumulative with dividends | -98.7% | -100.0% |
| CAGR (3Y)Annualised 3-year return | -76.2% | -63.0% |
Evenly matched — ASBP and YCBD each lead in 3 of 6 comparable metrics.
Risk & Volatility
YCBD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
YCBD is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than ASBP's 1.74 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. YCBD currently trades 32.4% from its 52-week high vs ASBP's 6.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ASBPAspire Biopharma … | YCBDcbdMD, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.74x | 0.66x |
| 52-Week HighHighest price in past year | $2.45 | $2.56 |
| 52-Week LowLowest price in past year | $0.05 | $0.47 |
| % of 52W HighCurrent price vs 52-week peak | +6.3% | +32.4% |
| RSI (14)Momentum oscillator 0–100 | 29.8 | 58.0 |
| Avg Volume (50D)Average daily shares traded | 15.0M | 1.7M |
YCBD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ASBPAspire Biopharma … | YCBDcbdMD, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +100.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
YCBD leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). ASBP leads in 1 (Profitability & Efficiency). 1 tied.
Best OverallcbdMD, Inc. (YCBD)Leads 3 of 6 categories
Loading custom metrics...
ASBP vs YCBD: Frequently Asked Questions
6 questions · data-driven answers · updated daily
01Which is the better long-term investment — ASBP or YCBD?
Over the past 5 years, Aspire Biopharma Holdings, Inc.
(ASBP) delivered a total return of -98. 7%, compared to -99. 9% for cbdMD, Inc. (YCBD). Over 10 years, the gap is even starker: ASBP returned -98. 7% versus YCBD's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — ASBP or YCBD?
By beta (market sensitivity over 5 years), cbdMD, Inc.
(YCBD) is the lower-risk stock at 0. 66β versus Aspire Biopharma Holdings, Inc. 's 1. 74β — meaning ASBP is approximately 163% more volatile than YCBD relative to the S&P 500.
03Which has better profit margins — ASBP or YCBD?
cbdMD, Inc.
(YCBD) is the more profitable company, earning -10. 6% net margin versus -16352. 0% for Aspire Biopharma Holdings, Inc. — meaning it keeps -10. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: YCBD leads at -11. 3% versus -10314. 4% for ASBP. At the gross margin level — before operating expenses — YCBD leads at 56. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
04Which pays a better dividend — ASBP or YCBD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
05Is ASBP or YCBD better for a retirement portfolio?
For long-horizon retirement investors, cbdMD, Inc.
(YCBD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66)). Aspire Biopharma Holdings, Inc. (ASBP) carries a higher beta of 1. 74 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (YCBD: -100. 0%, ASBP: -98. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
06What are the main differences between ASBP and YCBD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.